Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Journal of Managed Care & Specialty Pharmacy|April 26, 2022
The effectiveness and value of tezepelumab for severe asthmaDavid M Rind, R Brett McQueen, Serina Herron-Smith, et al.Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque PsoriasisNathaniel Hendrix, Daniel A Ollendorf, Richard H Chapman, et al.Journal of Managed Care & Specialty Pharmacy|December 24, 2021
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and valueFoluso Agboola, Steven J Atlas, Elizabeth Brouwer, et al.JAMA Network Open|February 23, 2019
Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell LymphomaMelanie D Whittington, R Brett McQueen, Daniel A Ollendorf, et al.JAMA Pediatrics|October 11, 2018
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory LeukemiaMelanie D Whittington, R Brett McQueen, Daniel A Ollendorf, et al.Clinical Trials (London, England)|August 3, 2017
Phase 1 healthy volunteer willingness to participate and enrollment preferencesStephanie C Chen, Ninet Sinaii, Gabriella Bedarida, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 4, 2022
The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United StatesOlena Mandrik, James Fotheringham, Shijie Ren, et al.Journal of Managed Care & Specialty Pharmacy|May 1, 2019
The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled AsthmaJeffrey A Tice, Jonathan D Campbell, Patricia G Synnott, et al.JAMA|August 18, 2016
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseDhruv S Kazi, Andrew E Moran, Pamela G Coxson, et al.Journal of Managed Care & Specialty Pharmacy|January 2, 2018
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United StatesJosh J Carlson, Gregory F Guzauskas, Richard H Chapman, et al.Pageof 14